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Abstract Several cytokines and growth factors activate tran- 
scription of their target genes via the JAK/STAT signalling 
pathway. It has been shown that the interaction between SH2 
domains of STAT factors and receptor phosphotyrosine r sidues 
plays an essential role in the specific recruitment of STATs. For 
STAT5, however, the importance of receptor tyrosines is still 
controversial. Using a chimeric receptor system in COS-7 cells, 
we studied the activation of STAT5 through the interleukin-6 
signal transducer gpl30. In contrast to previous reports, we did 
not detect gpl30-mediated STAT5 activation. However, STAT5 
activation was achieved when tyrosine motifs of other cytokine 
receptors were fused to the membrane-proximal part of gpl30. 
The comparison of the relative potency of different tyrosine 
motifs revealed that hydrophobic amino acids, preferentially 
leucine, in positions +1 and +3, and an aspartate residue in 
position -1  or -2  with respect to the tyrosine are likely to be 
required for efficient STAT5 recruitment. In summary, we show 
here for the first time that phosphotyrosine motifs can confer the 
ability to activate STAT5 to a heterologous receptor. 
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1. Introduction 
A variety of cytokines, growth factors, and hormones bind 
to structurally related receptors of the hematopoietin receptor 
superfamily, the members of which are characterized by four 
conserved cysteine residues and a WSXWS motif in their ex- 
tracellular domains [1]. Ligand binding to these receptors re- 
suits in homo- or heterodimerization of the receptor molecules 
[24]. Subsequently cytoplasmic protein kinases which belong 
to the JAK family of tyrosine kinases become activated. 
JAK1, JAK2, JAK3, and TYK2 [5] are constitutively asso- 
ciated with the membrane-proximal portions of cytokine re- 
ceptor cytoplasmic domains (box 1/2) [6,7]. After activation 
they phosphorylate the receptor molecules and a number of 
intracellular proteins, including the members of a family of 
transcription factors known as STATs (signal transducers and 
activators of transcription) [8]. All STAT factors contain a 
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SH2 domain which enables them to homo- or heterodimerize 
after tyrosine phosphorylation, with the SH2 domain of one 
STAT molecule binding to the phosphotyrosine residue of the 
other STAT [9]. STAT dimers then translocate to the nucleus 
where they bind to the promoter egions of their target genes 
[10-12]. Up to now, seven members of the STAT family of 
transcription factors have been cloned from mammalian cells, 
STAT1, STAT2, STAT3, STAT4, STAT5A, STAT5B, and 
STAT6. Furthermore, a STAT-like factor, d-STAT or Ma- 
relle, has recently been detected in insect cells [13]. 
Interestingly, several STAT factors can be activated by var- 
ious cytokines which signal via distinct JAK kinases. For ex- 
ample, erythropoietin, prolactin, growth hormone, and IL2 all 
trigger the phosphorylation and activation of STAT5. The 
erythropoietin, growth hormone, and prolactin receptors are 
associated with JAK2 while the IL2 receptor is known to 
recruit JAK1 and JAK3 [14]. On the other hand, IL4 does 
not activate STAT5 although the IL4 receptor is associated 
with JAK1 and JAK3, too. In view of these data, the question 
arises of how specificity in signalling via the JAK-STAT path- 
way is achieved. 
The experimental finding that the cytoplasmic parts of cy- 
tokine receptors not only contain a JAK binding domain, but 
also selectively bind different kinase substrates, provides a 
possible explanation of how specific STAT factors can be 
activated by specific cytokines. For the signal transducing 
subunit of the receptor complexes for IL6-type cytokines, 
gpl30, it has been shown that the receptor phosphotyrosine 
motifs YXPQ are able to bind STAT1 and STAT3, whereas 
the motifs YXXQ recruit STAT3 only. In both cases binding 
of the STATs leads to their activation by the receptor-asso- 
ciated JAK kinases [15,16]. 
In the case of STAT5, the discussion about whether its 
activation depends on receptor phosphotyrosine r sidues is 
still unresolved. STAT5 was originally discovered as mam- 
mary gland factor in mammary epithelial cells, where it is 
activated by prolactin [17]. Several other cytokines and 
growth factors also lead to the activation of STAT5, e.g. 
IL2, erythropoietin, GM-CSF, and growth hormone. For 
the erythropoietin and growth hormone receptors, and the 
IL2 receptor I~-chain, it has been shown that specific tyrosine 
residues which become phosphorylated after ligand binding 
are necessary for the activation of STAT5 [18-23]. On the 
other hand, it has been described that STAT5 activation via 
gpl30 occurs independently of any receptor phosphotyrosine 
residues [24]. Some investigators eported that in the case of 
growth hormone receptor phosphotyrosines do not play a role 
in STAT activation, either [25]. 
In order to analyze activation of STAT5 via gpl30 and to 
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determine how STAT5 is recruited to cytokine receptors and 
whether receptor phosphotyrosine r sidues are necessary for 
its activation, we created a series of chimeric receptors based 
on a truncated receptor which is not able to activate STAT 
factors on its own and of tyrosine motifs taken from different 
cytokine receptors which are able to mediate STAT5 activa- 
tion. In our experimental system the ability to activate STAT5 
could be transferred to the truncated receptor construct by 
different tyrosine modules which showed some homology, in- 
dicating that receptor tyrosine motifs play an important  role 
for the activation of STAT5. Activation of STAT5 through 
gpl30, however, could not be observed. 
2. Materials and methods 
2.1. Reagents 
Restriction enzymes and T4-DNA ligase were purchased from 
Boehringer Mannheim (Mannheim, Germany). Oligonucleotides 
were obtained from MWG Biotech (Ebersberg, Germany). The mono- 
clonal antibody M2 against he FLAG epitope (N-DYKDDDDK-C) 
was from Kodak (New Haven, CT, USA). DMEM and DMEM/F12 
mix were from Gibco (Eggenstein, Germany), fetal calf serum from 
Seromed (Berlin, Germany). Recombinant human IL6 was prepared 
as described by Arcone et al. [26]. Its specific activity was 1 × 10 ~ B- 
cell stimulatory factor-2 units/mg protein. Prolactin was purchased 
from Sigma (Deisenhofen, Germany). Recombinant human erythro- 
poietin was kindly provided by Drs. J. Burg and K.-H. Sellinger 
(Boehringer Mannheim, Penzberg, Germany). Erythropoietin receptor 
cDNA was a generous gift of Dr. H. Lodish (Boston, MA, USA). 
2.2. Cell culture 
COS-7 cells (ATCC CRL 1651) were grown in Dulbecco's modified 
Eagle's medium at 5% CO2 in a water-saturated atmosphere. Cell 
culture media were supplemented with 10% fetal calf serum, strepto- 
mycin (100 mg/l) and penicillin (60 mg/1). 
2.3. Expression vectors 
Standard cloning procedures were performed as outlined by Sam- 
brook et al. [27]. Construction of the expression vectors pSVL-Eg- 
Flag and pSVL-AB-Flag has been described previously [16]. For the 
construction of pSVL-Eg-YCTFP, -YLSLQ, -YSTVV, -YIDVQ, 
-YLVLD, -YVEIH, -YLSLP, and -YTSIH, oligonucleotides coding 
for the different yrosine motifs and containing an Nsil and a SalI 
site were introduced in the Nsil and Sail digested pBI30AS plasmid 
described previously [16]. The mutants were subcloned into pSVL-Eg 
as outlined by Gerhartz et al. [16]. 
2.4. Tran~fection 
Cells were transfected by electroporation with the Gene Pulser from 
Bio Rad Laboratories (Munich, Germany). 2×10 ~ cells in 0.8 ml 
DMEM were cotransfected with 20 ~tg of pECE vector containing 
STAT5A cDNA and 10 ~tg of pSVL vector containing erythropoietin 
receptor/gpl30 chimera cDNAs or prolactin receptor cDNA, or 10 p~g 
of pXM vector containing erythropoietin receptor cDNA using a 
voltage of 230 V and a capacity of 960 laF. 
2.5. Preparation of nuclear extracts 
Nuclear extracts of HepG2, H35 and COS-7 cells were prepared as 
described by Andrews and Faller [28]. Protein concentrations were 
measured by the Bio Rad protein assay. 
2.6. Electrophoretic mobility shift assay (EMSA) 
EMSAs were performed as described previously [16]. We used dou- 
ble-stranded 32p-labeled probes: the bicore probe, which consists of 
two core elements of the ot2-macroglobulin promoter in a 14 bp span 
(5'-AGC TGC AGT TCT GGG AAA GTC CTT AAT CCT TCT 
GGG AAT TCT-3'), and a mutated SIE oligonucleotide of the c-jos 
promoter (m67SIE: 5'-GAT CCG GGA GGG ATT TAC GGG 
GAA ATG CTG-3') [29]. Protein-DNA complexes were separated 
on a 4.5% polyacrylamide gel containing 7.5°/,, glycerol in 0.25-fold 
TBE at 20 V/cm for 4 h. Gels were fixed in 10% methanol, 10% acetic 
acid and 80% water for 1 h, dried and autoradiographed. 
2.7. Western blots 
Aliquots of cell lysates were electrophoresed on a 7.5%, SDS-poly- 
acrylamide gel and the proteins were transferred to a polyvinylidene 
difluoride membrane (Qiagen, Hilden, Germany). The membranes 
were reacted with the M2 monoclonal anti-FLAG antibody and 
then processed for chemiluminescent reactions. 
3. Results 
3.1. Lack o f  STAT5 activation via gpl30 in tran,sfected COS-7 
cells 
In order to establish a system suitable for the examination 
of STAT5 activation, we transfected COS-7 cells with expres- 
sion vectors for STAT5A and for the murine prolactin and 
erythropoietin receptors, respectively. Three days after trans- 
fection cells were stimulated with erythropoietin or prolactin 
for 15 min, then nuclear extracts were prepared and analyzed 
by EMSAs. In the band shift assays we employed a synthetic 
oligonucleotide as diagnostic substrate consisting of two 'core' 
STAT binding sites of the rat az-macroglobul in promoter [11] 
in a 14 bp span (bicore probe). A similar probe has been 
shown to bind STAT5 with high affinity [24]. 
The prolactin and erythropoietin receptors were both able 
to mediate STAT5A activation after stimulation with the re- 
spective hormone. In nuclear extracts of control cells trans- 
fected with STAT5A cDNA only, no activated STAT5 was 
detectable after st imulation with erythropoietin or prolactin 
(data not shown). 
To study STAT5 activation as mediated by gpl30, we used 
chimeric receptors consisting of the extracellular domain of 
the erythropoietin receptor and the t ransmembrane and cyto- 
plasmic regions of gpl30 (Fig. 1). These chimeric constructs 
permitted us to analyze the activation of STAT factors inde- 
pendently of endogenous gpl30 [16]. To prove that the ery- 
thropoietin receptor/gpl30 chimera (Eg) is functionally active, 
we stimulated transfected COS-7 cells with erythropoietin and 
compared the activation of endogenous STATs with the pat- 
tern of untransfected COS-7 cells stimulated with IL6 and 
EPO- 
Eg AB tyrosine 
modules 
box1 
box2 
gp13( 
flag 
epitol: 
Fig. 1. Chimeric receptors. The chimeras consist of the extracellular 
domain of the erythropoietin receptor and the transmembrane and 
cytoplasmic parts of gp 130. They contain a FLAG epitope at their 
C-terminal ends. The 'tyrosine module' chimeras have been con- 
structed with the aid of synthetic oligonucleotides. They have been 
sequenced throughout their synthetic regions. 
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cytokine IL6/sgp80 EPO EPO EPO EPO EPO 
stimulation + + + + + + 
receptor Eg Eg 513 Z~B Eg-YLVLD 
STATS + + + 
)robe StE SIE bicore SIE bicore bicore 
1 2 3 4 5 6 7 8 9 10 11 12 
Fig. 2. Activation of STAT factors via gp 130 and the Eg chimera. 
Untransfected COS-7 cells were stimulated with IL6 (100 B-cell 
stimulatory factor-2 units/ml) and soluble IL6 receptor (1 l.tg/ml). 
Nuclear extracts were prepared. The pattern of STAT activation 
was analyzed by EMSA and compared to that obtained via the Eg 
chimera in transfected cells (lanes 1~,). In addition AB, a truncated 
mutant of Eg, was examined with regard to its ability to activate 
STAT factors (lanes 7-10). As a positive control for STAT5A acti- 
vation another chimeric receptor consisting of the truncated Eg chi- 
mera and the YLVLD tyrosine motif (Y343 of the erythropoietin 
receptor) was created. Y343 is known to be crucial for STAT5 acti- 
vation via the erythropoietin receptor. COS-7 cells were transfected 
with Eg-YLVLD. Nuclear extracts were prepared after stimulation 
with erythropoietin (7 U/ml) and analyzed by EMSA (lanes 11,12). 
soluble IL6 receptor. As shown by EMSAs using the high 
affinity SIE probe, in both cases comparable STAT activation 
could be observed (Fig. 2, lanes 1,3). The single band appear- 
ing after stimulation has previously been demonstrated to be 
STATI  [16,30]. 
We then cotransfected COS-7 cells with expression vectors 
for STAT5 and the Eg chimera and stimulated with erythro- 
poietin. Neither STAT5A (Fig. 2) nor STAT5B (data not 
shown) was detectably activated as analyzed by EMSAs 
with the bicore probe. This observation is in contrast to the 
findings of other investigators who could demonstrate STAT5 
activation through gpl30 [24]. These authors also described 
that the gpl30-mediated activation of STAT5 did not depend 
on the tyrosine residues of the receptor. Therefore, we ana- 
lyzed a carboxy-terminally truncated form of the Eg chimera 
which retained box 1/2 of gpl30 but was devoid of the five 
carboxy-terminal tyrosine residues (see Fig. 1, AB). After stim- 
ulation with erythropoietin o activated STAT factors could 
be detected in EMSAs with the SIE and bicore probes (Fig. 2, 
lanes 7-10). 
To demonstrate that the chimeric receptor is able to me- 
diate STAT5 activation in principle, we added the tyrosine 
motif  YLVLD to the carboxyterminally truncated form of 
the chimera. The motif  YLVLD corresponds to Y343 of the 
erythropoietin receptor and was shown to be crucial for 
STAT5 activation by several authors [18-20]. Stimulation 
with erythropoietin led to a strong activation of STAT5 via 
this receptor mutant (Fig. 2, lanes 11,12). STAT5B was also 
activated although to a lesser extent (data not shown). 
3.2. Tyrosine motifs mediate STAT5 activation 
To examine the mode of STAT5 activation by other recep- 
tors, we constructed further chimeras (Fig. 1). Each of them 
consists of the extracellular domain of the erythropoietin re- 
ceptor, the transmembrane and cytoplasmic regions of gpl30, 
the latter of which was truncated after box 1/2, a synthetic 
oligonucleotide representing a tyrosine motif  taken from a 
STAT5 activating receptor and a FLAG epitope. In many 
cases positions +1 and +3 within phosphotyrosine motifs 
have been found to determine the specificity of SH2 do- 
main/phosphotyrosine interactions. Therefore, we searched 
for tyrosine motifs which bear some similarity with the 
YLVLD motif  at positions +1 and +3 in a variety of cytokine 
receptors. COS-7 cells were cotransfected with expression vec- 
tors for STAT5A and for the different constructs. The expres- 
sion of the different chimeric receptors as analyzed by Wes- 
tern blotting using an antibody to the FLAG epitope was 
found to be comparable (Fig. 3B). After stimulation of the 
transfected cells with erythropoietin for 15 min nuclear ex- 
tracts were analyzed by EMSAs using the bicore probe. 
As shown in Fig. 3A several tyrosine motifs were able to 
recruit STAT5A to the receptor and mediate its activation: 
the motifs YLVLD (erythropoiefin receptor), YLSLP (GM- 
CSF receptor) and YLSLQ (IL2 receptor, I]-chain) proved to 
be very efficient. A high level of STAT5A activation was also 
obtained with YVEIH (prolactin receptor) and YCTFP (IL2 
receptor, 13-chain). Y IDVQ (LIF receptor) was found to be 
only weakly active, and no STAT5A activation could be de- 
A B q 
IL2-R IL.2-R UF-R ~ GM"CSF-R PRL-R EPO'R  9P130 ~)  I~ , ~ ~. >- >- ~_. 
p-cha~ p.c~i. I~  
YCTFP YLSLQ Y IDVQ YTS IH  Y I .SLP YVE IH  YLVLD YSTW 
+ + + + + + + + 
66kD 
46kD 
Fig. 3. A: STAT5 activation by chimeric receptors. COS-7 cells were transfected with expression vectors for STAT5A and different chimeric re- 
ceptors. After 3 days the transfected cells were stimulated with erythropoietin (7 U/ml) for 15 min~ Nuclear extracts were prepared and ana- 
lyzed by EMSAs using the bicore probe. B: Expression of chimeric receptors in COS-7 cells. COS-7 cells were transfected with the cDNA for 
the respective chimeric receptors. After 3 days cell lysates were prepared and the expression of the constructs was checked by Western blotting 
using a FLAG antibody. The double bands seen in this figure correspond to differentially glycosylated forms of the chimeric receptors. Yoshi- 
mura et al. [34] showed for the erythropoietin receptor, whose extracellular part the chimeras hare, that Golgi-processed erythropoietin recep- 
tor molecules differ from their precursors in molecular weight and that both forms are found in erythropoietin receptor expressing cells. 
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Table 1 
Tyrosine module Receptor Activation of STAT5 
DTYLVLD EPO-R (Y343) +++ 
QDYLSLP GM-CSF-R, [3c-chain ++(+) 
(Y882) 
DAYLSLQ IL2-R, ]3-chain (Y510) ++(+) 
DAYCTFP IL2-R, [3-chain (Y392) ++ 
LDYVEIH PRL-R (Y496) ++ 
VIYIDVQ LIF-R (Y974) (+) 
PDYTSIH GH-R (Y595) - 
VQYSTVV gpl30 (Y759) 
tected using the YTSIH (GH receptor) and YSTVV (gpl30) 
constructs. 
The identity of activated STAT5 was confirmed by immu- 
noprecipitation with the phosphotyrosine antibody PY20, 
subsequent Western blotting and detection by a STAT5 anti- 
body (Transduction Laboratories) (data not shown). 
4. Discussion 
Several cytokines are capable of inducing STAT5 phos- 
phorylation via kinases of the JAK family, which are consti- 
tutively associated with the cytoplasmic tail of cytokine recep- 
tors and become activated after ligand-induced dimerization 
of the receptor molecules. Depending on the cytokine receptor 
with which a specific JAK kinase is associated, tyrosine phos- 
phorylation of different STAT factors by this kinase can oc- 
cur. It is currently believed that the specificity of STAT acti- 
vation is determined by receptor tyrosine residues which are 
also phosphorylated by JAK kinases. The receptor phospho- 
tyrosines represent docking sites for the SH2 domains of the 
respective STAT factors. 
For STAT1 and STAT3 it has already been described that 
distinct receptor tyrosine motifs mediate differential activation 
of these two transcription factors [15,16]. Here we have shown 
that the ability to selectively activate STAT5 can be trans- 
ferred by the addition of tyrosine motifs derived from 
STAT5-activating receptors to a chimeric receptor construct 
(Fig. 1, AB) which cannot recruit STAT factors on its own. 
Substantial sequence similarity exists among the different y- 
rosine modules that conferred the ability to activate STAT5. 
In the tyrosine motifs which mediate STAT5 activation most 
efficiently, YLVLD (Y343 of the erythropoietin receptor), 
YLSLQ (Y510 of the IL2 receptor 13-chain), and YLSLP 
(Y882 of the GM-CSF receptor [3-chain), leucine is found at 
positions +1 and +3 with respect to the tyrosine residue. 
Other amino acids with aliphatic side chains are part of the 
motifs YVEIH (Y509 of the prolactin receptor) and YIDVQ 
(Y974 of the LIF receptor), which also recruit STAT5 with 
YVEIH being more effective than YIDVQ. Surprisingly, the 
motif YCTFP (Y392 of the IL2 receptor [3-chain) is also able 
to activate STAT5 in spite of a hydrophilic ysteine at posi- 
tion +1 (Table 1). It is to be noted that all five motifs mediat- 
ing efficient STAT5 activation contain an acid residue (aspar- 
tate) in position -1  or --2 while the motif YIDVQ (Y974 of 
the LIF receptor), which is least effective, does not (see Table 
1). Therefore, this residue may also contribute to STAT5 re- 
cruitment o the receptor. 
Y343 of the erythropoietin receptor has been described to 
P. May et al./FEBS Letters 394 (1996) 221-226 
be crucial for STAT5 activation via erythropoietin by different 
authors [18-20]. Using truncated erythropoietin receptor con- 
structs and receptor molecules in which tyrosine residues had 
been point-mutated, it was shown that Y343 is sufficient for 
STAT5 phosphorylation, but controversy exists with respect 
to the question whether this tyrosine is also necessary for the 
recruitment of STAT5. Gobert et al. [20] found that Y401 of 
the erythropoietin receptor (YTILD) is able to activate 
STAT5, too, and can replace Y343. Interestingly, this motif 
contains a glutamic acid in position -1 .  On the other hand, 
Quelle et al. [19], using phosphopeptide competition assays, 
could not demonstrate hat the phosphorylated YTILD-motif 
impairs dimerization of STAT5. They also showed that the 
modules pYLVVS (Y431) and pYVACS (Y479) are efficient 
competitors. In contrast o these observations Gobert et al. 
[20] found that Y431 and Y479 are not able to activate 
STAT5. Damen et al. [18], for their part, describe Y343 as 
necessary for the recruitment of STAT5 at low erythropoietin 
concentrations, but state that high concentrations of the 
growth factor lead to receptor tyrosine independent activation 
of STAT5, suggesting a loss of specificity under these condi- 
tions. Thus, the importance of Y343 of the erythropoietin 
receptor for STAT5 phosphorylation is widely accepted. How- 
ever, the contribution of other tyrosine residues, of which 
Y431 (YLVVS) resembles our modules more closely than 
Y401 (YTILD) or Y479 (YVACS), is evaluated controver- 
sially by authors using either phosphopeptide competition as- 
says or band shift assays as method of investigation. 
In accordance with our results Gaffen et al. [31] and Fried- 
mann et al. [22] showed by analysis of receptor mutants and 
phosphopeptide competition assays that Y392 (YCTFP) and 
Y510 (YLSLQ) are crucial for the activation of STAT5 by the 
IL2 receptor [3-chain. It is remarkable that the two motifs do 
not show obvious sequence homology, but it should be noted 
that in both cases the two amino acids on the N-terminal side 
of the tyrosine residue are identical: DAYLSLQ and 
DAYCTFP. This may be a further indication that amino 
acids N-terminal of the tyrosine may play a role in STAT5 
activation. Alternatively, STAT5 may be activated by differ- 
ent motifs, as has been shown for STAT1 which is recruited 
by a motif YXPQ in gpl30 and the LIF receptor, whereas 
YDKPH represents he respective motif in the IFN3t receptor 
[15,16,32]. 
For the prolactin and GM-CSF receptors no receptor tyro- 
sine motifs crucial for STAT5 activation have been described 
so far. We have shown in this paper that Y509 of the prolac- 
tin receptor and Y882 of the GM-CSF receptor 13-chain are 
sufficient o mediate the activation of STAT5. Further studies 
with receptor mutants need to be done in order to find out 
whether the mentioned motifs are also necessary for the re- 
cruitment of STAT5 by the respective receptor. 
Interestingly, the YIDVQ motif of the LIF receptor me- 
diates weak STAT5 activation, suggesting that STAT5 might 
play a role in LIF signal transduction. Further studies are 
needed to elucidate this possibility. 
The two tyrosine motifs YTSIH (Y595 of the growth hor- 
mone receptor) and YSTVV (Y759 of gpl30), which are not 
able to mediate STAT5 activation, differ from most other 
modules in the hydrophilic amino acid at position +1 (threo- 
nine or serine, respectively). This finding suggests that the 
amino acid at position +1 is of special importance within 
the motif recognized by the SH2 domain of STAT5. 
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For the growth hormone receptor, Hansen et al. [21] 
showed that Y534 (YFCEA), Y566(YITTE), and Y627 
(YVSTD) are able to mediate STAT5 activation independ- 
ently of each other. In accordance with our results the amino 
acid at position +1 is hydrophobic in all three motifs, but 
hydrophilic residues are found at position +3. These findings 
also provide evidence for a hydrophobic residue at position 
+ 1 being more important than one at position +3. Smit et al. 
[33] reported that Y333 (YKPDF) and Y338 (YNDDS) of the 
murine growth hormone receptor may also be able to mediate 
STAT5 activation. Although these motifs are totally unrelated 
to those described herein, they share the aspartate in position 
-2 .  These authors also note that this residue might be im- 
portant and speculate that non-SH2-type interactions might 
be involved. 
The failure of YSTVV (Y759 of gpl30) to activate STAT5 
is not surprising since no STAT activation could be achieved 
with the receptor construct containing the complete cytoplas- 
mic domain of gp130 in COS-7 cells. These findings, however, 
contrast with the results of Lai et al. [24], who could demon- 
strate STAT5 activation by,a receptor construct consisting of 
the extracellular domain of the G-CSF receptor instead of the 
erythropoietin receptor used in our experiments and the in- 
tracellular part of gpl30 in COS-1 cells. In addition, these 
authors found STAT5 activation by gpl30 to be independent 
of receptor tyrosine residues by using a truncated mutant of 
their receptor construct. This contradiction to our data could 
be explained by a possible influence of the extracellular do- 
main of a chimeric receptor on intracellular signalling. Alter- 
natively, the assay system of Lai et al. [24] may measure 
STAT5 activation with greater sensitivity. Thus, the definite 
role of STAT5 in IL6 signal transduction needs to be clarified 
by further experiments. The inability of the cytoplasmic part 
of gpl30 to recruit STAT5 in our experimental system 
allowed us to analyze phosphotyrosine motifs from other 
cytokine receptors with the aid of mutants of the Eg chime- 
ra .  
In summary, we conclude from our experimental findings 
that the specificity of STAT5 activation in the JAK/STAT 
signalling pathway is mediated by receptor phosphotyrosine 
motifs. These motifs have a modular character, as the ability 
to activate STAT5 can be transferred to receptor constructs 
not capable of recruiting STAT factors by addition of a tyro- 
sine motif of another eceptor which activates STAT5. In the 
motifs sufficient o mediate STAT5 activation, leucine is re- 
peatedly found at positions +1 and +3 relative to the tyrosine 
residue, but also other hydrophobic amino acids, especially 
those with aliphatic side chains, seem to be acceptable. 
From these data we derive the consensus equence YZXZ 
for STAT5 activation with Z standing for a hydrophobic 
amino acid, preferably an aliphatic one, with the addition 
that acid residues in position -1  or --2 may also be impor- 
tant. The chimeric receptor system described here is likely to 
prove highly valuable in determining the exact requirements 
of STAT5 activation. 
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